According to the present invention, there are provided a chamber for transplantation which has a high durability, and in which an enclosed biological constituent can be maintained for a long period of time because an interior space thereof is efficiently secured; and a method for manufacturing the chamber for transplantation. The chamber for transplantation includes one or more membranes for immunoisolation at a boundary between an inside and an outside of the chamber for transplantation, in which all of the membranes for immunoisolation include a porous membrane containing a polymer, and a joint portion at which the porous membranes are directly fusion welded to each other is provided. The method for manufacturing a chamber for transplantation includes preparing one or more porous membranes containing a polymer selected from polysulfone and polyethersulfone, bringing one part of the porous membrane into direct contact with another part of the porous membrane, and performing a heat fusion welding of the two parts that are in direct contact with each other at a temperature which is a glass transition temperature of the polymer or higher and lower than a melting point of the polymer.

There is provided a mutant KLF protein that can induce reprogramming of a somatic cell at a higher efficiency than a KLF protein having a natural amino acid sequence. There is also provided a method for efficiently producing an iPS cell by using the mutant KLF protein. There is provided a mutant KLF protein having an amino acid substitution, or a peptide fragment thereof containing the amino acid substitution.

A DNA methylation editing kit comprises: (1) a fusion protein of inactivated CRISPR-associated endonuclease Cas9 (dCas9) having no nuclease activity and a tag peptide array in which plural tag peptides are linked by linkers, or an RNA or DNA coding therefor; (2) a fusion protein(s) of a tag peptide-binding portion and a methylase or demethylase, or an RNA(s) or DNA(s) coding therefor; and (3) a guide RNA(s) (gRNA(s)) comprising a sequence complementary to a DNA sequence within 1 kb of a desired site of methylation or demethylation, or a DNA(s) expressing the gRNA(s).

A DNA methylation editing kit comprises: (1) a fusion protein of inactivated CRISPR-associated endonuclease Cas9 (dCas9) having no nuclease activity and a tag peptide array in which plural tag peptides are linked by linkers, or an RNA or DNA coding therefor; (2) a fusion protein(s) of a tag peptide-binding portion and a methylase or demethylase, or an RNA(s) or DNA(s) coding therefor; and (3) a guide RNA(s) (gRNA(s)) comprising a sequence complementary to a DNA sequence within 1 kb of a desired site of methylation or demethylation, or a DNA(s) expressing the gRNA(s).

The present invention relates to a cell culturing method and kit. More specifically, it relates to a cell culturing method and kit using a support that is exposed to the air. It further relates to a method of culturing cells by allowing them to migrate onto a porous polyimide film.

The present invention provides a method of controlling bacterial contamination using synergistic interactions of antimicrobials. The invention consists of combinations of chlorine dioxide and organic acid whose combined antimicrobial effect is greater than the sum of their individual activities, i.e., synergistic.

The invention provides a ligand-bonded fiber in which a ligand having affinity for a cell membrane receptor is immobilized on a fiber precursor, and a cell culture substrate capable of repeating ex vivo amplification of a cell expressing a cell membrane receptor by using the ligand-bonded fiber.

A therapeutic vaccination method includes growing and harvesting viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium; killing the viruses, bacteria, fungi, parasites, or tumor cells in the cell culture or other appropriate medium with a dose of methylene blue; separating the dead viruses, bacteria, fungi, parasites, or tumor cells from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge; adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic therapeutic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form a therapeutic vaccine; and administering the therapeutic vaccine to a patient in need thereof to simultaneously produces a therapeutic response and a humoral and cellular immune response in the body of the patient without resulting in deleterious side effects to the patient.

A therapeutic vaccination method includes growing and harvesting viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium; killing the viruses, bacteria, fungi, parasites, or tumor cells in the cell culture or other appropriate medium with a dose of methylene blue; separating the dead viruses, bacteria, fungi, parasites, or tumor cells from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge; adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic therapeutic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form a therapeutic vaccine; and administering the therapeutic vaccine to a patient in need thereof to simultaneously produces a therapeutic response and a humoral and cellular immune response in the body of the patient without resulting in deleterious side effects to the patient.

The present invention relates to nanoparticles and their use to form nanocomposite material, in particular bionanocomposite material, specifically wherein the nanoparticles are formed using plant virus attached to a scaffold of cellulosic material and/or cellulose derived materials, in particular wherein said cellulosic material further comprises plant cell components, for example hemicellulose, pectin, protein or combinations thereof.